Profile data is unavailable for this security.
About the company
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
- Revenue in USD (TTM)0.00
- Net income in USD-101.60m
- Incorporated2014
- Employees95.00
- LocationKorro Bio IncOne Kendall Square. Building 600-700Suite 6-401CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 468-1999
- Fax+1 (302) 636-5454
- Websitehttps://www.korrobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | 43.00k | -283.43m | 442.41m | 232.00 | -- | 0.9532 | -- | 10,288.56 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 446.78m | 52.00 | -- | 5.03 | -- | 45.06 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Omeros Corp | 0.00 | -185.38m | 447.93m | 198.00 | -- | -- | -- | -- | -3.14 | -2.30 | 0.00 | -2.66 | 0.00 | -- | -- | 0.00 | -45.98 | -55.51 | -61.42 | -70.10 | -- | -- | -- | -- | -- | -6.07 | 1.59 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Aura Biosciences Inc | 0.00 | -83.22m | 447.94m | 88.00 | -- | 2.57 | -- | -- | -1.73 | -1.73 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -43.22 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -122.68m | 450.69m | 87.00 | -- | 2.27 | -- | -- | -2.19 | -2.19 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -46.92 | -30.06 | -51.51 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.55m | -23.86m | 452.37m | 100.00 | -- | 4.89 | -- | 5.35 | -0.541 | -0.541 | 1.92 | 2.06 | 0.677 | 1.13 | 4.36 | 845,530.00 | -19.11 | -44.23 | -23.55 | -50.45 | 88.89 | -- | -28.22 | -181.13 | 3.54 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Regenxbio Inc | 84.33m | -238.81m | 454.82m | 344.00 | -- | 1.51 | -- | 5.39 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| OmniAB Inc | 20.41m | -63.02m | 454.93m | 106.00 | -- | 1.59 | -- | 22.29 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| MeiraGTx Holdings PLC | 13.93m | -88.18m | 456.93m | 389.00 | -- | 4.80 | -- | 32.80 | -1.30 | -1.30 | 0.2123 | 1.23 | 0.0492 | -- | 1.08 | 33,243.44 | -31.12 | -26.40 | -39.74 | -32.66 | -7.72 | -- | -633.05 | -420.70 | -- | -- | 0.4324 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 457.69m | 150.00 | -- | 2.32 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 462.38m | 180.00 | -- | 1.77 | -- | 2.88 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Korro Bio Inc | 0.00 | -101.60m | 470.71m | 95.00 | -- | 2.63 | -- | -- | -17.04 | -17.04 | 0.00 | 19.28 | 0.00 | -- | -- | 0.00 | -70.10 | -31.55 | -76.20 | -36.48 | -- | -- | -- | -365.87 | -- | -104.93 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Celcuity Inc | 0.00 | -93.97m | 471.39m | 55.00 | -- | 3.16 | -- | -- | -2.61 | -2.61 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -45.24 | -37.32 | -49.93 | -39.16 | -- | -- | -- | -- | -- | -- | 0.393 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -88.07m | 481.92m | 66.00 | -- | 1.33 | -- | -- | -1.18 | -1.18 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -27.10 | -41.34 | -28.12 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Data as of Nov 22 2024. Currency figures normalised to Korro Bio Inc's reporting currency: US Dollar USD
48.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 30 Sep 2024 | 850.00k | 9.14% |
| Point72 Asset Management LPas of 30 Sep 2024 | 721.68k | 7.76% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 579.56k | 6.23% |
| Citadel Advisors LLCas of 30 Sep 2024 | 529.17k | 5.69% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 429.75k | 4.62% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 411.77k | 4.43% |
| Eventide Asset Management LLCas of 30 Sep 2024 | 391.17k | 4.21% |
| Cormorant Asset Management LPas of 30 Sep 2024 | 265.83k | 2.86% |
| Driehaus Capital Management LLCas of 30 Sep 2024 | 154.50k | 1.66% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2024 | 142.65k | 1.53% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
